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PAX5 is one of the most frequently mutated genes in B‑cell acute lymphoblastic leukemia (B‑ALL), 
and children with inherited preleukemic PAX5 mutations are at a higher risk of developing the disease. 
Abnormal profiles of inflammatory markers have been detected in neonatal blood spot samples 
of children who later developed B‑ALL. However, how inflammatory signals contribute to B‑ALL 
development is unclear. Here, we demonstrate that Pax5 heterozygosis, in the presence of infections, 
results in the enhanced production of the inflammatory cytokine interleukin‑6 (IL‑6), which appears to 
act in an autocrine fashion to promote leukemia growth. Furthermore, in vivo genetic downregulation 
of IL-6 in these Pax5 heterozygous mice retards B‑cell leukemogenesis, and in vivo pharmacologic 
inhibition of IL‑6 with a neutralizing antibody in Pax5 mutant mice with B‑ALL clears leukemic cells. 
Additionally, this novel IL–6 signaling paradigm identified in mice was also substantiated in humans. 
Altogether, our studies establish aberrant IL6 expression caused by Pax5 loss as a hallmark of Pax5‑
dependent B‑ALL and the IL6 as a therapeutic vulnerability for B‑ALL characterized by PAX5 loss.
Hematopoietic development is a tightly regulated process requiring precise control, both at the cell-intrinsic 
(transcriptional and epigenetic) and extrinsic (cytokines and other permissive or inductive signals) levels, and 
any alteration of these controls leads to unfavorable outcomes. B-cell acute lymphoblastic leukemias (B-ALLs) are 
clonal malignancies caused by the loss of appropriate control over the proliferation and/or differentiation along 
B cell  development1. Genetic alterations in regulators of B-lymphoid development are present in approximately 
two-thirds of cases of B-ALL2. PAX5 is arguably one of the most important transcription factors required for cor-
rect B cell  development3, and it can be involved in B-ALL at different stages of the disease, being altered in more 
than one-third of B-ALL cases by deletion, sequence mutations, or translocation with different fusion  partners3–6. 
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Besides these somatically acquired PAX5 mutations, it has been shown that inherited hypomorphic variants of the 
gene predispose the carriers to the development of familiar B-ALL7,8. Studies both in affected human carriers and 
in animals carrying an heterozygous null mutation of Pax5 (Pax5+/- mice, henceforth also called “Pax5 mutant 
mice”) have shown that Pax5 mutant mice tend to accumulate an expanded, aberrant, vulnerable, population 
of B cell progenitors prone to malignant transformation through the accumulation of secondary mutations in 
the presence of a selective  pressure7–9. These accumulated cells are commonly defined as preleukemic  cells10, 
and the selection and expansion of these preleukemic-B clones precede the development of B-ALL, both in the 
case of carriers of congenital PAX5 mutations, and also in almost all other B-ALL-predisposing somatically 
arising mutations studied to  date10–12. Preleukemic cells remain latent until they progress to the development of 
full-blown B-ALL through acquisition of additional somatic mutations over  time1. We have recently shown that 
natural exposure to infectious pathogens contribute to the ‘‘switch’’ from a preleukemic state to a leukemic state in 
cells bearing these PAX5  mutations9,13, and Pax5 mutant mice go on to develop B-ALL with modest penetration 
when they are exposed to natural  infections9, usually associated with the inactivation of the other copy of Pax5. 
In this context, inflammation has been hypothesized to play an essential  role14–16, but precisely how inflamma-
tory signals influence the Pax5 mutant B-cell leukemogenesis process is poorly understood. Human populations 
with different ancestries have been naturally selected to present many allelic differences in the genes involved 
in immune system development and immune  response17. All these variants allow specific responses (stronger 
or weaker) against certain types of  infections17, but can also increase the chances of developing certain diseases; 
in the case of B-ALL, this can be caused by an imbalance in the immune system that helps disease progression. 
Given the limited genetic variation present in experimental mice, the results from these models suggest that 
the contribution of the rest of the individual genetic variations beyond the preleukemia-initiating one does not 
seem to play a major role in the transition from the preleukemic phase to B-ALL, a fact further supported by 
the possibility of triggering B-ALL conversion ex vivo with TLR  ligands18–20. Considering that Pax5-mutant 
preleukemic cells give rise to infection-triggered B-ALL in both human and  mice7–9, the relationship between 
inflammation and B-cell leukemogenesis is likely to be B-cell-dependent. Because preleukemic precursor B cells 
reside in the bone marrow, an inflammatory microenvironment can influence the growth of these cells in part 
by producing pro-inflammatory cytokines. In the present study, we asked whether the inflammatory signals 
contribute to B-ALL development triggered by environmental infection exposure as a result of Pax5-inherited 
susceptibility. The results from our experiments identify IL-6 as a key cytokine whose expression and secretion 
by mouse leukemic B-cells is induced when Pax5 is lost during the course of B-ALL development, and whose 
inhibition therapeutically targets leukemic cells.
RESULTS
Pax5+/‑ mice developing B‑ALL show enhanced expression of the proinflammatory cytokine 
IL‑6. To determine whether the transformation of preleukemic B cells to full-blown B-ALL is in part due to 
dysregulated expression of inflammatory cytokines in Pax5+/- mice, we measured concentrations of 7 inflam-
matory cytokines (IL-2, IL-4, IL-6, IL-10, IL-17a, TNF and IFNγ) in the serum of Pax5+/- mice exposed to an 
infectious environment which developed B-ALL, exposed Pax5+/- mice without B-ALL, and age-matched con-
trol wild-type mice. We found that leukemic Pax5+/- mice had abnormal concentrations of IL-6 (Fig. 1a and Sup-
plementary Fig. 1). The emergence of this increase in IL-6 levels could further be linked to disease onset, since 
IL-6 in serum samples taken at routine intervals confirmed lack of IL-6 increase in the exposed Pax5+/- mice that 
never developed B-ALL (Fig. 1a-b, Supplementary Table S1 and Supplementary Fig. 1). However, IL-6 increase 
was not detectable in serum samples taken at routine intervals in healthy (non-leukemic) Pax5+/- mice that later 
developed B-ALL, prior to the first phenotypic signs of illness (Fig. 1b and Supplementary Fig. 2). In addition, 
this increase in IL-6 was not observed in mouse models where the appearance of B-ALL is triggered by infection 
exposure but is not linked to a congenital Pax5 alteration, like in Sca1-BCR-ABLp190 and Sca1-ETV6-RUNX1 
mice where the second hit does not involve Pax5 inactivation (Fig. 1c)21. However, elevated levels of IL-6 protein 
could be measured at the time of B-ALL diagnosis in the serum of Pax5+/-;Sca1-ETV6-RUNX1 leukemic mice 
and Pax5+/-;Sca1-BCR-ABLp190 leukemic  mice22 (Fig. 1, Supplementary Table S1). These elevated levels of IL-6 
protein could be recapitulated at the time of diagnosis in the serum of human B-ALL carrying PAX5 altera-
tions (and lacking known JAK/STAT mutations) compared to Healthy Donors (HD) (Fig. 1d, Supplementary 
Table S2). Thus, induction of a leukemogenic state by Pax5-loss is associated with an increase in IL-6 secretion 
in both human patients and mouse models, suggesting the IL-6 secretion may correspondingly be the product 
of oncogenic Pax5 inactivation.
Pax5 controls IL‑6 expression in B‑cells. We investigated the mechanisms controlling IL-6 production 
using leukemic proB cells and both control wild-type and Pax5+/- proB-cells. Leukemic proB cells, lacking Pax5 
activity due to secondary mutations of the WT Pax5  allele9, displayed high levels of IL-6 mRNA cells (Fig. 2a), 
which was not significant in Pax5+/+ leukemic cells and it was not detectable neither in control wild-type proB-
cells nor in control Pax5+/- proB-cells (Fig. 2a). However, high levels of IL-6 mRNA are present in healthy Pax5-/- 
precursor B cells (Supplementary Fig. 3). A microarray analysis of gene expression confirmed enrichment of the 
IL-6 signaling pathway geneset only in leukemic proB cells (Fig. 2b and Supplementary Fig. 4A-B) as well as an 
enrichment in inflammatory response and apoptosis gene sets (Supplementary Fig. 4C-D). We then investigated 
leukemic proB cells lacking Pax5 activity for expression of a panel of effectors genes known to regulate IL-6 
expression, and we found a significant downregulation of both Blnk (which is a Pax5 direct  target23) and Bcl6 
expression (Fig. 2c-d). BCL6 is a direct transcriptional repressor of the IL-6  gene24 and recent work has shown 
that STAT5 activation inhibits BCL6  expression25. Therefore, Pax5-deficient leukemic proB cells had decreased 
Bcl6 levels and this, together with the STAT5 activation, could contribute to the upregulation of IL-6 expression 
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observed in Pax5-deficient leukemic proB cells. These results indicate that Pax5 activity controls IL-6 expression 
in proB cells, and suggest that both Bcl6 and STAT5 activation are involved in the complex molecular network 
mediating this effect. Taken together, these data suggest that IL-6 might be important for Pax5-deficient B-ALL 
development. Thus, we next examined whether IL-6 plays any role in Pax5-mediated B-cell leukemogenesis.
Impairment of IL‑6 signaling in Pax5+/‑ mice delays natural infection‑driven B‑ALL develop‑
ment. Given the observed upregulation of IL-6 in Pax5-deficient leukemic proB cells and mice, we next 
directly tested the requirement for IL-6 in Pax5-loss mediated leukemia growth in a system that recapitulates the 
Figure 1.  IL-6 serum levels in mice and humans with B-ALL. (a) IL-6 serum levels in IL-6+/-, IL-6-/- and Pax5+/- 
non-leukemic mice and Pax5+/- mice that develop B-ALL vs control wild-type mice. All mice were exposed to 
an infectious environment as described in the Methods section. (b) IL-6 serum concentrations in Pax5+/- and 
control wild type mice at different ages vs leukemic Pax5+/- mice. (c) IL-6 levels in serum from Sca1-BCR/
ABLp190 + Pax5+/+, Sca1-BCR/ABLp190 + Pax5+/-, Sca1-ETV6-RUNX1 and Sca1-ETV6-RUNX1 + Pax5+/- mice. (d) 
Serum levels of IL-6 in human B-ALL patients who carry PAX5 alterations vs healthy donors. Notched-boxes 
extend from the 25th to the 75th percentile values; the lines in the middle and vertical lines correspond to 
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Figure 2.  Pax5 controls IL-6 expression in B-cells. (a) Relative expression of mIL-6 in leukemic Pax5+/- and 
Pax5+/+ (BCR-ABLp190 +) cells obtained from different individual mice (mouse codes shown on the X axis) 
compared to proB cells from healthy Pax5+/- and WT proB cells. The total bone marrow of a WT mouse was 
used as a reference. Error bars represent the mean + /- the standard deviation of 3 replicates. (b) GSEA showing 
that leukemic Pax5+/- cells are enriched in the IL-6_JAK_STAT3 signaling geneset (FDR = 0.002). (c) Relative 
expression of mBcl6 in leukemic Pax5-/- proB cells and compared with healthy Pax5+/- and WT proB cells. The 
total bone marrow of a WT mouse was used as a reference. Error bars represent the mean + /- the standard 
deviation of 3 replicates. (d) Relative expression of mBlnk in leukemic Pax5-/- proB cells and compared with 
healthy Pax5+/- and WT proB cells. The total bone marrow of a WT mouse was used as a reference. Error bars 
represent the mean + /- the standard deviation of 3 replicates.
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spontaneous process of leukemogenesis. To functionally demonstrate the role of IL-6, we impaired the expres-
sion of IL-6 by breeding Pax5+/- mice to IL-6+/− mice, which have significantly lower IL-6 serum concentrations 
(Fig. 1a), with the aim of testing whether IL-6+/-/Pax5+/- mice are more resistant to infection-induced B-ALL 
than Pax5+/- mice. Accordingly, control IL-6+/+/Pax5+/- and experimental IL-6+/-/Pax5+/- mice were exposed to 
natural infections, and B-ALL development was monitored as previously  described9. The results showed that 
the reduction on IL-6 levels significantly delayed the emergency of leukemias in Pax5+/- mice upon expo-
sure to natural infections (Fig. 3). B-ALL appeared between 6 and 16  months of age in IL-6+/+/Pax5+/- mice 
(mean = 11.29 months) and, at the end of the 24 months’ experimental period, 22% of the mice had developed 
B-ALL (Fig. 3a-b), in line with previously reported results. In sharp contrast, B-ALL was significantly delayed 
in the IL-6+/-/Pax5+/- mice, appearing between 18 and 22  months of age (mean = 20.13  months) (Fig.  3a-b), 
although by the termination of the experiment a similar percentage (20%) of the mice had developed B-ALL and 
IL-6 was elevated in their serum similarly to IL-6+/+/Pax5+/- leukemias (Fig. 3c). These IL-6+/-/Pax5+/- B-ALLs 
are histologically, phenotypically and genetically similar to IL-6+/+/Pax5+/- B-ALLs, and FACS analyses revealed 
a  CD19+/-B220+IgM-cKit+/-CD25+/- cell surface phenotype for tumor cells that extended through bone marrow 
(BM), peripheral blood (PB), spleen and lymph nodes (Supplementary Fig. 5) and infiltrated non-lymphoid tis-
sues like liver and intestine (Supplementary Fig. 6). All IL-6+/-/Pax5+/- B-ALLs displayed clonal immature BCR 
rearrangements (Supplementary Fig. 7). We then characterized the global expression signature of IL-6+/-/Pax5+/- 
B-ALLs and compared it with the expression signature of both healthy WT pro-B/pre-B cells and IL-6+/+/Pax5+/- 
leukemias. The analysis showed a similar differential gene expression profile (FDR = 0.05) between expression 
patterns in IL-6+/-/ Pax5+/- B-ALL, and Pax5+/- B-ALL with just 196 probe-sets differentially expressed (Sup-
plementary Fig. 8A and Supplementary Table S3) in contrast to the huge differences in terms of gene expres-
sion between IL-6+/-/Pax5+/- B-ALL and healthy WT proB cells with 9160 probe-sets differentially expressed 
(Supplementary Fig. 8B and Supplementary Table S4). We next aimed to confirm that the specific significant 
delay in B-ALL development due to IL-6+/- heterozygosity does not modify the B-cell susceptibility and genetic 
characteristics of B-ALL in Pax5+/- mice; similar to IL-6+/+/Pax5+/- mice, preleukemic IL-6+/-/Pax5+/- littermates 
presented a significantly reduced amount of total B-cells in the PB when compared to Pax5+/+ (WT) littermates 
of the same breeding (Supplementary Fig. 9), but this PB B-cell decrease was similar to the one observed in 
IL-6+/+/Pax5+/- mice (Supplementary Fig. 9). In order to further identify somatically acquired 2nd hits leading 
to leukemia development, we next performed whole exome sequencing of 4 IL-6+/-/Pax5+/- B-ALLs and cor-
responding germline on a HiSeq 2500 (Illumina) platform. IL-6+/-/Pax5+/- tumor DNA was derived from whole 
leukemic BM or lymph nodes, while tail DNA of the respective mouse was used as reference germline material. 
Similar to IL-6+/+/Pax5+/-  leukemias9, IL-6+/-/Pax5+/- tumors showed recurrent mutations affecting Pax5, Ss18, 
Jak1, and Jak3 (Fig. 4). Taken together, these data demonstrate that the decrease of IL-6 delays spontaneous 
formation of infection-driven B-ALL in Pax5+/- mice. Collectively, our data suggest that knocking down ampli-
fied IL6 levels represents a formidable barrier to Pax5-dependent leukemogenesis, a finding of clear clinical 
relevance. 
Pax5 mutant B‑ALL is not sensitive to IL‑6 inhibition in transplant‑based mouse models. To 
test the hypothesis that IL-6 inhibition may represent a preferential target for Pax5-dependent B-ALLs, and to 
expand our studies to more clinically relevant settings, we first tested whether IL-6 contributes to Pax5-depend-
ent B-ALL maintenance, since IL-6 is a secreted protein, and as such it is amenable to targeting by neutralizing 
 antibodies26 and, moreover, such an antibody treatment has already been shown to be tolerated in  humans27. 
In the past, the efficiency of experimental therapies against B-ALL has been routinely measured by transplant-
ing leukemic B cells into recipient mice that had been preconditioned by  irradiation28,29. However, a potential 
limitation of this approach to studies focused on how inflammatory signaling affects B-ALL, resides in the fact 
that irradiation triggers the production of pro-inflammatory cytokines such as IL-1, IL-6 and  TNF30,31. Never-
theless, to be consistent with previous studies in the literature, we first tested the efficacy of the neutralizing IL-6 
antibody in mice infused with leukemic Pax5+/− proB cells harboring the Jak3V670A  mutation9 (Supplementary 
Fig. 10A). These leukemic proB cells were isolated from the BM of diseased mice, as  B220+, by MACS-sorting, 
then cultured in medium containing IL-7 and, later, propagated in IL-7-independent culture  conditions9. These 
leukemic Pax5+/− pro-B cells harboring Jak3V670A cells were injected into syngenic mice (n = 10), and the animals 
were randomized to treatment at day 14 when the disease was confirmed by the presence of blast cells in the PB 
(Supplementary Fig. 10). Mice were treated with two doses of the anti–IL-6 antibody at 10 mg/kg, 3 days apart. 
FACS analysis of the PB was used to verify disease remission during therapy. Anti–IL-6 antibody therapy pro-
vided no significant survival advantage and none of all mice treated (n = 5) showed a decrease in the percentage 
of blast cells (Supplementary Fig. 10B), even though the anti-IL-6 treatment significantly reduced the levels of 
IL-6 in the serum of treated mice (Supplementary Fig. 10C and Supplementary Table S5). However, an impor-
tant caveat to take into account when interpreting this result is the fact that we found that the standard culture 
conditions with IL-7 used to isolate leukemic proB cells from mice abolished the IL-6 production both in vitro 
(Supplementary Fig. 11 and Supplementary Table S5) and in vivo (Supplementary Fig. 10C and Supplementary 
Table S5). These findings are in agreement with previous observations showing that cytokine-mediated survival 
signals do not compete between  them32. These observations explain why the use of anti–IL-6 antibody therapy 
was not able of modifying the course of the disease, and underscore the limitations of the use of ex vivo func-
tional studies involving leukemic pro-B cell in vitro expansion and bone marrow transplantation to identify 
how inflammatory signaling affects B-ALL development. Therefore, as previously  suggested33, transplant-based 
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Figure 3.  Impairment of IL-6 signaling in Pax5+/- mice delays natural infection-driven B-ALL development. (a) 
B-ALL-specific survival of IL-6+/- (light blue line, n = 15), IL6+/+/Pax5+/- (red line, n = 39), IL-6+/-/Pax5+/- (purple line, 
n = 20) and wild-type mice (black line, n = 20), all of them exposed to common infections. Log-rank (Mantel-Cox) 
test p-value = 0.00373 when comparing IL-6+/-/Pax5+/- vs WT and p-value = 0.0271 when comparing IL6+/+/Pax5+/- vs 
WT and p-value = 0.7157 when comparing IL-6+/-/Pax5+/- vs IL-6+/+/Pax5+/-. (b) The median age of IL-6+/-/Pax5+/- 
and IL6+/+/Pax5+/- mice at B-ALL diagnosis. Error bars represent the mean and SD. For the significant differences, 
unpaired t-test p-values are indicated. c) IL-6 serum levels in non-leukemic mice (IL-6+/+ /Pax5+/-, IL-6+/-/Pax5+/-) and 
leukemic mice (IL6+/+/Pax5+/-, IL-6+/-/Pax5+/-) vs control wild-type mice. Notched-boxes extend from the 25th to the 
75th percentile values; the lines in the middle and vertical lines correspond to median values and the 10th and 90th 
percentiles, respectively. The Kruskal–Wallis test was used to interpret differences.
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IL‑6 inhibition therapeutically targets Pax5‑dependent B‑ALL in vivo. Our previous results indi-
cate that a complete understanding of how the modulation of the inflammatory signaling affects Pax5 mutant 
B-ALL can only come from the analysis of intact, unmanipulated animals. Thus, we next explored if the block-
ade of IL-6 could modify the course of a native non-transplant Pax5-dependent B-ALL disease. To this aim, 
IL-6+/+/Pax5+/- mice were randomized to treatment with either immunoglobulin G (IgG) control antibody or 
an anti-IL-6 antibody, twice a week (10 mg/kg) once the B-ALL disease appeared as a result of natural infection 
 exposure9, as confirmed by the presence of blast cells in the PB (Supplementary Fig. 12A). The IgG control-
treatment did not modify the course of the disease with independence of the percentage of blasts at diagnosis. 
However, we found that the anti–IL-6 antibodies abolished the increase in IL-6 serum levels characteristic of 
Pax5-dependent B-ALL (Fig. 5a). Blockade of IL-6 in vivo reduced disease progression in 100% of the anti-IL-
6-treated mice when the percentage of blast cells in PB was lower than 40% at the time of treatment (Fig. 5b-c 
and Supplementary Fig. 12B-D). However, disease progression could not be modified by IL-6 inhibition when 
Figure 4.  Mouse tumor exome sequencing in IL-6+/-/Pax5+/- B-ALL. (a) Whole-exome sequencing analysis of 
tumor and control samples. Tumor-specific somatic mutations were determined by mutect and varscan analysis. 
The number of somatic cancer genes was calculated by using the cancer gene consensus list. The percentage 
of leukemic cells for each mouse was: 98% (U971) from total BM, 90% (U572) from total BM, 90% (L370) 
from total BM and 20% (L371) from total LN. (b) Genomic comparison between mutations driving native 
B-ALL as a result of natural infection exposure of IL-6+/+/Pax5+/- (previously described in Martin-Lorenzo, A. 
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Figure 5.  Anti-IL-6 antibody is able to eliminate blast cells in Pax5+/- leukemic mice. (a) IL-6 serum levels in 
Pax5+/- leukemic mice treated with anti-IL-6 (n = 5–3). Error bars represent the mean and SD. For the significant 
differences, an unpaired t-test was used (***; p-value < 0.0001). (b) B-ALL cells were decreased in 3 out of 6 
Pax5+/- mice after anti-IL-6 treatment. (c–d) FACs analysis of PB and BM showing the reduction of blast cells in 
a responder Pax5+/- leukemic mouse due to anti-IL-6 treatment.
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the percentage of blast cells in PB was higher than 70% at the time of treatment (Fig. 5b-c and Supplementary 
Fig. 12E-G). In order to further clarify if the relapse (the reoccurrence of disease in the responders) after IL-6 
inhibition is driven by pre-existing leukemic cells or by the selection of IL6-resistant clones through the acqui-
sition of new mutations, we next performed whole exome sequencing of the 6 IL-6+/+/Pax5+/- tumors before 
anti-IL-6-treatment and after relapse. Tumor DNA was derived from whole leukemic PB, while tail DNA of 
the respective mouse was used as reference germline material. Leukemias at relapse showed similar recurrent 
mutations than leukemias before anti-IL-6-treatment (Supplementary Fig.  13 and Supplementary Table  S6). 
Thus, these data further suggest that IL-6 retains driver functions in established leukemia and demonstrate the 
application of this in vivo native assay to identify the importance of players relevant for B-ALL development. 
These results show that IL-6-neutralizing antibodies may be useful therapeutic options in the treatment of Pax5-
dependent leukemias.
Discussion
Proleukemic inflammatory environment in Pax5‑mutant B‑cell leukemogenesis. Our results 
uncover an essential mechanism involving the proinflammatory cytokine IL-6 in sustaining Pax5-dependent 
B-ALL development. Abnormal profiles of inflammatory markers, including higher concentrations of IL-6, 
IL-17, and IL-18, have already been detected in neonatal blood spot samples of children who later developed 
B-cell precursor  ALL34, and in vitro studies have also shown that pro‐inflammatory cytokines like IL-6/IL-1β/
TNFα35 or TGF-β dependent  signaling36,37, can predispose pre‐leukemic B cells to malignant transformation. 
However, the real contribution of these inflammatory pathways to B-ALL development remains unclear. In this 
study, we examined the impact of inflammation on the conversion of Pax5+/- preleukemic cells. PAX5 is fre-
quently mutated in a large percentage of B-ALL  cases3–6, but these mutations can also be present in normal 
children who will never develop B-ALL7,8, very much like the ETV6-RUNX1 translocation only causes B-ALL 
in a small percentage of  carriers38. It is known that infection exposure pushes the progression from preleuke-
mic state to full-blown B-ALL in a significant fraction of Pax5+/- or ETV6-RUNX1+  cases9,13,21. Here, we have 
examined how the inflammatory profile changes the behavior of preleukemic cells in a Pax5+/- mouse model. We 
identify IL-6 as a key cytokine whose expression and secretion by mouse leukemic B-cells is induced when Pax5 
is lost during the course of B-ALL development. Serum IL-6 levels and the expression of IL-6 are significantly 
upregulated in both Pax5-deficient leukemic and healthy B-cells. The presence of IL-6 was further confirmed 
in serum of B-ALL patients where PAX5 function is lost. Mechanistically, we show unambiguously by a genetic 
approach in the Pax5+/- mouse that impairment of IL-6 signaling delays B-ALL development, hence confirming 
the essential contribution of this pathway as a feedback loop supporting B-ALL development. An important 
aspect that should be taken into consideration is that, although our data show that Pax5 indeed regulates IL6 
expression, it cannot be rouled out that the microenvironment, following infections and/or leukemia, might 
also contribute to the observed IL6 increase. Nevertheless, our findings, taken together, demonstrate that Pax5-
dependent B-ALLs are profoundly affected by the proleukemic inflammatory environment in which leukemic 
progenitor cells reside, and also support the view that increased levels of the pro-inflammatory cytokine IL-6 are 
an essential trigger of the B-ALL disease observed in Pax5+/- mice.
IL‑6 signaling as a target for Pax5‑mutant B‑ALL therapy. IL-6 has been previously implicated in 
the pathogenesis of hematological malignancies, like multiple  myeloma39, Hodgkin’s  lymphoma40,  CML41,42, 
 CMML43, and solid cancers, like  breast44,  prostate45, and pancreatic  cancer46. Likewise, it has been suggested 
that increased autocrine IL-6 expression in PAX5 − mantle cell lymphoma (MCL) cells may contribute to the 
reduction in TP53 gene expression and could provide survival advantages to lymphoma  cells47. In this study, we 
identify IL-6 as a major player in Pax5-dependent B-ALL pathogenesis, and we demonstrate that Pax5 activity 
dictates the level of IL-6 produced by both mouse and human leukemic B-cells, regulating IL-6 mRNA levels 
through BCL6 and the STAT5 pathway, which are two well known transcriptional regulators of the IL-6  gene24,48. 
Furthermore, we find that disruption of the IL-6 loop through genetic downregulation of the IL-6 gene in Pax5+/- 
mice significantly delays B-ALL onset, and that blocking IL-6 signaling kills Pax5-dependent B-ALL in unma-
nipulated animals. All these results show that the IL-6 signaling pathway represents a therapeutic vulnerability 
in Pax5-dependent B-ALL, and that its targeting could be a promising therapy for this disease, which could also 
be extended to other hematological diseases, taking into account the high frequency of somatic PAX5 losses-of-
function in different types of B cell leukemias.
Material and methods
Mouse model for natural infection‑driven leukemia. Pax5+/-  mice49 were crossed with IL-6-/-  mice50 
to generate Pax5+/-/IL-6+/- mice. These Pax5+/-/ IL-6+/- and Pax5+/- mice were bred and maintained in the SPF 
area of the animal house until the moment when they were relocated to an environment where natural infec-
tious agents were present, as previously  described9. Animal studies were performed in accordance with rel-
evant guidelines and regulations and approved by the pertinent institutional committees of both University of 
Salamanca and Spanish Research Council (CSIC). IL-6+/-, IL-6-/-, Pax5+/-/IL-6+/-, and Pax5+/- mice of a mixed 
C57BL/6 × CBA background were used in this study, with approximately equal representation of both males and 
females. For the experiments, IL-6+/-, IL-6-/-, Pax5+/-/IL-6+/-, and Pax5+/- of the same litter were used. When the 
animals showed evidences of illness, they were humanely killed, and the main organs were extracted by standard 
dissection. All major organs were macroscopically inspected under the stereo microscope, and then representa-
tive samples of tissue were cut from the freshly dissected organs, and were immediately fixed. Differences in 
Kaplan–Meier survival plots of transgenic and WT mice were analyzed using the log-rank (Mantel-Cox) test. 
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Also samples from Pax5+/+;Sca1-BCR-ABLp190, Pax5+/-;Sca1-BCR-ABLp190, Pax5+/+;Sca1-ETV6-RUNX1 and 
Pax5+/-;Sca1-ETV6-RUNX1 leukemic mice were used to measured cytokine serum levels.
Flow cytometry and cell sorting. Flow cytometry and cell sorting was carried out as previously 
 described9,13. Total mouse BM cells were obtained by washing the long bones with PBS with 1% FCS, using a 
27-G needle. Cells were as well collected from peripheral blood, and also from the thymus and spleen after dis-
rupting these organs by passing them through a 70-μm cell strainer. Erythrocytes were osmotically lysed using 
RCLB buffer, and nucleated cells were then washed with PBS–1% FCS. Cells were stained with the appropriate 
antibodies against the indicated cellular markers for 20 min at 4 °C, washed once with PBS–1% FCS, and finally 
they were resuspended in PBS–1% FCS with 10 μg/mL propidium iodide (PI) to exclude dead cells during data 
acquisition; this was performed in an AccuriC6 Flow Cytometer, and data files were analyzed using Flowjo 
software. For this analysis, gates were set by employing the commonly used forward and perpendicular light-
scattering properties of mouse hematopoietic cells, and the specific fluorescence of the staining dyes used [FITC, 
PE, PI, and APC excited at 488 nm (0.4 W) and 633 nm (30 mW), respectively]; an example of such a gating 
strategy is shown in Supplementary Fig. 14. The nonspecific binding of staining antibodies to the Fc receptors of 
immune cells was prevented by incubating the samples with anti-CD16/CD32 Fc-block solution (clone 2.4G2, 
cat. #553,142, BD Biosciences) for 20 min at 4 °C, previously to the addition of the staining antibodies. For each 
sample tube, a minimum of 50,000 living (i.e., PI-negative) cells were acquired and analyzed.
The antibodies used for flow cytometry were all from BD Biosciences: anti-B220 (clone RA3-6B2, cat. 
#103,212, used in 1:100 dilution), CD4 (clone RM4-5, cat. #100,516, used in 1:250 dilution), CD8a (clone 53–6.7, 
cat. #100,708, used in 1:250 dilution), CD11b/Mac1 (clone M1/70, cat. #553,310, used in 1:200 dilution), CD19 
(clone 1D3, cat. #152,404, used in 1:100 dilution), CD117/c-Kit (clone 2B8, cat. 105,807, used in 1:200 dilution), 
Ly-6G/Gr1 (clone RB6-8C5; cat. #108,412, used in 1:100 dilution), IgM (clone R6-60.2, cat. #406,509, used in 
1:100 dilution) and CD25 (clone PC61, cat. #553,866, used in 1:100 dilution). The gating strategy is exemplified 
in Supplementary Fig. 14.
Real‑ time PCR quantification (Q‑PCR) of mIL-6, mBcl6 and mBlnk. Real- time PCR quantification 
(Q-PCR) was carried out as previously  described9,13. We analyzed the expression of mIL-6, mBcl6 and mBlnk 
in leukemic Pax5+/- cells as well as in healthy Pax5+/- and WT proB cells by Q-PCR as follows: cDNA was syn-
thesized using reverse transcriptase (Access RT-PCR System; Promega, Madison, WI) and genomic DNA was 
removed by DNAase treatment (Roche, 04 716 728 001). Real-time PCR reactions were performed in an Eppen-
dorf MasterCycler Realplex machine. Commercially available assays for quantitative PCR from IDT (Integrated 
DNA Technologies) were used: mIL-6 (Assay ID: Mm.PT.58.10005566), mBcl6 (Assay ID: Mm.PT.58.32669842), 
mBlnk (Assay ID: Mm.PT.58.7821272) and Gapdh (Assay ID: Mm.PT.39a.1). Probes were specifically designed 
to prevent detection of genomic DNA by PCR. Measurement of Gapdh gene product expression was used as 
an endogenous control and the total bone marrow of a WT mouse was used as a reference to calculate the 
fold change. We also analyzed the murine IL6 expression in healthy precursor Pax5-/- B cells using a qRT-PCR 
assay (Roche; cat. no. 04685032001) recognizing the Gene identified as ENSMUSG00000025746 (GRCm38.
p6), and detecting all the existing 4 transcript isoforms IL6-201 (ENSMUSG00000026845.11), IL6-202 (ENS-
MUSG000000195978.4), IL6-203 (ENSMUSG000000199183.4), IL6-204 (ENSMUSG000000199765.1). The 
Taqman assay used the following primers: mIL6-L6 (5′-GCT ACC AAA CTG GAT ATA ATC AGG A-3′) and mIL6-
R6 (5′- CCA GGT AGC TAT GGT ACT CCA GAA -3′) and in this case measurement of Hprt gene product expres-
sion was used as an endogenous control and murine mesenquimal stem cells (mMSC) were used as a reference 
to calculate the fold change. All samples were run in triplicate. The comparative CT Method (ΔΔCt) was used 
to calculate relative expression of the transcript of interest and a positive control. The change in threshold cycle 
(ΔCt) of each sample was calculated as the Ct value of the tested gene (target) minus the Ct value of Gadph 
(endogenous control). The ΔΔCt of each sample was obtained by subtracting the ΔCt value of the reference from 
the ΔCt value of the sample. The ΔCt reference value used was the ΔCt obtained from total BM of a WT mouse. 
The fold change in each group, calculated as 2–ΔΔCt sample, was compared.
Histology. Histology was carried out as previously  described9,13. Animals were sacrificed by cervical dislo-
cation; tissue samples were formalin-fixed and included in paraffin. Pathology assessment was performed on 
hematoxylin–eosin stained sections under the supervision of Dr. Oscar Blanco, an expert pathologist at the 
Salamanca University Hospital.
Quantification of cytokine levels in serum. Quantification of cytokine levels in serum was carried out 
as previously  described41. Serum cytokine levels were analysed using The Cytometric Bead Array immunoassay 
system (CBA) (BD Biosciences) which assesses simultaneously IL-2, IL-4, IL-6, IL-10, IL-17A, TNF alpha and 
IFN gamma in serum from the mice (Mouse Th1 Th2 Th17 Cytokine Kit #560,485; BDB); and serum from the 
patients and controls (Human Th1 Th2 Th17 Cytokine Kit #560,484; BDB). Human studies were performed in 
accordance with relevant guidelines and regulations and approved by the Comisión de donación de muestras 
del Institute Josep Carreras (IJC). Serum was obtained from children and adults and all participants or their 
legal guardians provided written informed consent to take part in the study. Data acquisition was performed 
on a FACSCanto II flow cytometer (BDB) using the FACSDiva™ software program (BDB). For the evaluation of 
cytokine serum levels or cytokine secretion into the culture supernatants, 50 µl of serum was collected. Briefly, 
50 µl of the serum was incubated at room temperature for 2 h at room temperature (RT) with 50 µl of anticy-
tokine MAb-coated beads and with 50 µl of the appropriate phycoerythrin (PE)- conjugated anticytokine anti-
body detector. After this incubation period, samples were washed once (5 min at 200 g) in order to remove the 
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excess of detector antibodies. Immediately afterwards, data acquisition was performed on a FACSCanto II flow 
cytometer (BDB) using the FACSDiva™ software program (BDB). During acquisition, information was stored for 
3,000 events corresponding to each bead population analysed per sample (total number of beads > 9,000). For 
data analysis, FCAP Array Software v3.0 program (BDB) was used.
Anti‑IL‑6R treatment. Anti-IL-6R antibody (Tocilizumab) was obtained from Chugai Pharmaceuticals 
Co. Ltd. (Shizuoka, Japan). Anti-IL-6R antibody was intraperitoneally administered at 10 mg/kg twice a week. 
Treatments were started after the establishment of B-ALL.
ProB cell culture. ProB cell culture was carried out as previously  described9,13. Pro-B cells were purified 
from BM using magnetic-activated cell sorting, selecting with anti-B220 beads (Milteny Biotec). Pro-B cells 
were maintained and expanded by culturing them in Iscove’s Modified Dulbecco’s Medium (IMDM) supple-
mented with 50 μM β-mercaptoethanol, 1 mM L-Gln, 2% heat-inactivated FCS, 1 mM penicillin–streptomycin 
(BioWhittaker), 0.03% (w/v) primatone RL (Sigma), and 5 ng/ml mrIL-7 (R&D Systems), in the presence of 
Mitomycin C-treated ST2-feeder cells. Tumor pro-B cells that could grow independently of IL-7 were grown in 
the same medium without this cytokine.
Transplantation. Transplantation was carried out as previously  described9,13. IL-7-independent leukemic 
pro-B cells were intravenously injected into 12-week-old male syngenic mice (C57BL/6 × CBA) that had previ-
ously been sublethally irradiated (4 Gy). Leukemia development in the injected mice was followed by regular 
analysis of peripheral blood, until the moment when leukemic blasts were detected in the blood; at this point, 
animals were treated with anti-IL-6R antibody.
V(D)J recombination. V(D)J recombination analysis was carried out as previously  described9,13. Immu-
noglobulin rearrangements were amplified by PCR using the primers below. Cycling conditions consisted of an 
initial heat-activation at 95 °C followed by 31–37 cycles of denaturation for 1 min at 95 °C, annealing for 1 min 
at 65 °C, and elongation for 1 min 45 s at 72 °C. This was followed by a final elongation for 10 min at 72 °C. The 
following primer pairs were used:
VHJ558
forward CGA GCT CTC CAR CAC AGC CTW CAT GCA RCT CARC 
reverse GTC TAG ATT CTC ACA AGA GTC CGA TAG ACC CTGG 
VH7183
forward CGG TAC CAA GAA SAMCCT GTW CCT GCA AAT-GASC
reverse GTC TAG ATT CTC ACA AGA GTC CGA TAG ACC CTGG 
VHQ52
forward CGG TAC CAG ACT GAR CAT CASCAA GGA CAA YTC C
reverse GTC TAG ATT CTC ACA AGA GTC CGA TAG ACC CTGG 
DH
forward TTC AAA GCA CAA TGC CTG GCT 
reverse GTC TAG ATT CTC ACA AGA GTC CGA TAG ACC CTGG 
Cμ
forward TGG CCA TGG GCT GCC TAG CCC GGG ACTT 
reverse GCC TGA CTG AGC TCA CAC AAG GAG GA
Microarray data analysis. Microarray data analysis was carried out as previously  described9,13. The total 
RNA was first isolated using TRIzol (Life Technologies), and then it was subjected to purification with the RNe-
asy Mini Kit (Qiagen) using also the On-Column DNase treatment option. Quality and quantification of RNA 
samples were determined by electrophoresis.
Determination of the expression of the different genes in the RNA samples was performed using Affym-
etrix Mouse Gene 1.0 ST arrays. All bioinformatic analyses of the array data were performed using  R51 and 
 Bioconductor52. First, we applied background correction, intra- and inter-microarray normalization, and expres-
sion signal calculation using the microarray analysis  algorithm53–55, in order to determine the absolute expression 
signal for each gene in each array. Then, we used the significance analysis of microarray (SAM)56 method to 
identify the gene probe sets with differential expression between experimental and control samples, SAM uses a 
permutation algorithm to allow to statistically infer the significance of the differential expression, and it provides 
P-values adjusted to correct for the multiple testing problem, by using  FDR57. An FDR cutoff of < 0.05 was used 
as a threshold to determine differential expression. The data discussed in this publication have been deposited in 
NCBI’s Gene Expression Omnibus (GEO)58 and are accessible through GEO Series accession number GSE154589.
Enrichment analysis. Enrichment analysis was carried out as previously  described9,13. In order to identify 
potential signatures of gene expression associated with different biological processes, gene set enrichment analy-
sis (GSEA) was performed using the MSigDB databases from the Broad Institute (GSEAv2.2.2)59 and hallmark 
collection of gene  sets60,61.
Mouse exome library preparation and NGS. Mouse exome library preparation and NGS was carried 
out as previously  described9,13. DNA was purified from samples using the AllPrep DNA/RNA Mini Kit (Qiagen) 
according to the manufacturer’s instructions. The exome library was prepared using the Agilent SureSelectXT 
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Mouse All Exon Kit with some modifications. Exome capture was performed by hybridization to an RNA library 
according to the manufacturer’s protocol. Then, the captured library was purified and enriched by binding to 
MyOne Streptavidin T1 Dynabeads (Life Technologies) and posterior off-bead PCR amplification in the linear 
range. Sequencing (2 × 100 bp) was carried out in a HiSeq2500 (Illumina) using the TruSeq SBS Kit v3 with a 
6-bp index read.
Data analysis. Data analysis was carried out as previously  described9,13. Fastq files were generated with 
Illumina BcltoFastq 1.8.4. The alignment of the sequence data to the GRCm38.71 mouse reference genome was 
performed with BWA version 0.7.4. SAMtools was used for conversion steps and removal of duplicate reads. 
GATK 2.4.9 was used for local realignment around indels, SNP-calling, annotation, and recalibration. For recali-
bration, mouse dbSNP138 and dbSNP for the used mouse strains were used as training data sets. The variation 
calls obtained in this way were then annotated using the v70 Ensembl database with variant effect predictor 
(VEP), incorporating loss-of-function prediction scores for PolyPhen2 and SIFT. Afterward, the information 
was imported into an in-house MySQL database for further annotation, reconciliation, and data analysis by 
complex database queries if required.
Somatic calls were the output from  MuTect62 and  VarScan63. For VarScan2 results, false-positive filtering was 
used as indicated by the author. In order to increase the reliability of the results, only calls having at least a 9% 
difference in allele frequency between tumor and normal samples were considered for further analysis. Cancer-
related genes were singled-out by using the information from the Catalogue of Somatic Mutations in Cancer 
(COSMIC)64,65 after having translated the cancer gene consensus from COSMIC by making use of Ensembl’s 
 BioMart66.
Statistical analysis. The Kruskal–Wallis test followed by Dunn’s multiple comparison test was used for 
multiple groups to interpret differences in IL6 serum levels using the  statistical software SPSS 23. Compari-
sons of survival curves estimated by Kaplan—Meier plots using Graph Pad Prism 5.0 were performed by the 
log-rank (Mantel-Cox) test. And the differences between two sample groups were made using an unpaired t-test 
with GrapPad Prism 5.0 software. The level of significance was set at p-value < 0.05.
Data availability
Authors can confirm that all relevant data are included in the paper and/or its supplementary information files. 
Gene Expression Data are accessible through GEO Series accession number GSE154589.
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